Dr Tim England TICH-2 SAE adjudicator

Slides:



Advertisements
Similar presentations
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Advertisements

Adverse Events and Serious Adverse Events
Safety Reporting IN Clinical Trials
AEs, SAEs, and EAEs – An Overview
ADVERSE EVENT REPORTING
Pharmacovigilance Dr. Muiris Dowling,
Adverse Event Reporting. Reporting Adverse Events Adverse Events (AEs) are “... any untoward medical occurrence in a subject that was not previously identified.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
Elements of a clinical trial research protocol
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
Basic Pharmacovigilance Training
Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Paula Nicholson Research Facilitator
SAE Report CTT21 V To:Quality Assurance Research & Development 34 Hyde Terrace LS2 9LN Date:…………………………….. Fax To:+44(0) From (name):………………………..
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
M ODULE H I NTERIM M ONITORING V ISIT Denise Thwing 21 Apr Version: Final 21-Apr-2010.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Paula Peyrani, MD Division of Infectious Diseases University of Louisville Performing the Study.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
Using the short form and reporting adverse events Erin Coons, Senior IRB Specialist, COMIRB 1.
Expedited Reporting of Adverse Events to the DAIDS
New Adverse Event Reporting Policy Effective September 1, 2007.
Adverse Event Reporting.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
1 MRC SUPREMO (BIG 2-04) Selective Use of Postoperative Radiotherapy aftEr MastectOmy Phase III randomised trial of chest wall RT in intermediate- risk.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
Andrace DeYampert Bethany Lane Samkeliso Mawocha ProTECT III Investigator Meeting November 12-14, 2012.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
Adverse Event Reporting & SAE Reporting for Investigators Trial Number: (POLO-AML-2) Date of training:23 February 2013 Trainer: Deepa Sachdev Venue:Investigator.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
EAE Training PROTOCOL ­ SPECIFIC Objectives  Definitions  Assessment of Adverse Events  EAE Reporting.
Agenda Introduction Study Objectives Study Design Delegation
Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet,
Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.
REPORTING ADVERSE EVENTS AND COMPLETING THE REPORT FORM
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
11 v. Train staff on the collection of data
Reportable Events Emory IRB 9/11/2014.
Safety Reporting V6.0 17/01/17.
Assessing expectedness of an adverse event
8. Causality assessment:
Safety Reporting Nichol McBee, MPH, CCRP.
Expedited Adverse Event Reporting Requirements
Remote Monitoring of Adverse Events
Copenhagen University Hospital Rigshospitalet, Denmark
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Expedited Adverse Event Reporting Requirements
*Continue on SAE supplemental page CTT21 A if more space is required
Remote Monitoring of Adverse Events
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
WHAT TO DO IF A PATIENT DEVELOPS AN UNEXPECTED PROBLEM?
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
Adverse Event Reporting _____________________________
Serious Adverse Event Reconciliation
Presentation transcript:

Dr Tim England TICH-2 SAE adjudicator SAE reporting Dr Tim England TICH-2 SAE adjudicator

Overview Adjudication Adverse Events Case examples Objective Review process of reporting/adjudication Information needed by adjudicator Adverse Events AE vs SAE vs SUSAR Case examples Objective Improve reporting process Reduce number of data queries Save time for investigators and trial staff Improve quality of data for trial Improve outcomes for people affected by stroke

What is adjudication? Definition: Evidence Process Judge reviews evidence Decision Evidence Nature of evidence will effect decision

How is adjudication performed? Independent adjudicator Consultant stroke physicians Review data on-line – via website Therefore vital that data entered on-line is appropriate and detailed

Why adjudicate? Pharmacovigilance Drug safety Collection, detection, assessment, monitoring, and prevention of adverse effects with pharmacological products Drug safety TARDIS - ? recurrent strokes TICH-2 - ? risk of VTE

What needs adjudicating? SAE – was it related to the drug? Outcome – is it confirmed? Need evidence to be able to judge Nature of evidence will effect decision High quality trials need high quality evidence

Adverse event: Definition Any untoward medical occurrence in a study subject administered an intervention and which does not necessarily have a causal relationship with this treatment A medical or surgical procedure is not an AE, the reason for the procedure is! Abnormal laboratory values are AEs if ‘clinically significant’, lead to treatment change, are a SAE, or are a safety risk

What to report? Do not collect all AE: Trials of known interventions that are already licensed and in routine clinical use GTN Aspirin, clopidogrel & dipyridamole Tranexamic acid Considerable information is already known for each Some specific AEs are collected: eg TARDIS minor bleeds Some trials not all SAEs reported: TICH-2 (though ALL safety outcomes are) – check protocol

Adverse Event or Serious AE? Common examples Headache UTI Nausea Vomiting Persistent weakness Not eating and drinking Poor progress with rehabilitation

SAE: Components - Question Any untoward medical occurrence that? Results in death Is life-threatening Requires inpatient hospitalisation or prolongation of existing hospitalisation Is an adverse event assessed as severe Results in persistent or significant disability/incapacity Is a congenital anomaly/birth defect Is medically important 10

SAE: Components - Question Any untoward medical occurrence that? Results in death Is life-threatening Requires inpatient hospitalisation or prolongation of existing hospitalisation Is an adverse event assessed as severe Results in persistent or significant disability/incapacity Is a congenital anomaly/birth defect Is medically important 11

SAE: Serious or Severe ‘Severe’ ‘Serious’ A medical judgement used to describe intensity (severity) of a specific event (as in mild, moderate, or severe myocardial infarction) The event itself, however, may be of relatively minor medical significance (e.g. ‘severe headache’). So severity does not mean serious ‘Serious’ Based on event outcome or action criteria usually associated with events that pose a threat to a patient's life or functioning What’s also worth mentioning at this stage to ensure that there is no confusion or misunderstanding of the difference between the terms "serious” and "severe” is this definition proposed by the ICH HARMONISED TRIPARTITE GUIDELINE CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING 12

SAE: Medically important Serious adverse events that may jeopardise the patient or may require medical or surgical intervention to prevent one of the other serious outcomes Examples: Allergic bronchospasm requiring intensive treatment in A&E Convulsion not resulting in in-patient hospitalisation An abnormal lab value which needs active out-patient management

When to report?

SUSAR Suspected Unexpected Serious Adverse Reaction: Unexpected Unlikely in context of antiplatelet agents Serious – needs to meet criteria for serious Fatal Life threatening Disabling Hospitalisation (admission or prolongation) Teratogenic Medically important Reaction Suspected drug reaction Not just a consequence or complication of stroke

Relationship / causality Relationship Other cause? Definitely v. strong none Probably strong unlikely Possibly suggestive equally likely Unlikely weak likely Not related none v. likely

Diagnostic evidence Give as much information as possible: Pathology PM, … Radiology CT, MR, Carotid, … ECG AF, MI, LVH, … Bacteriology … Biochemistry LFTs, CRP, … Haematology FBC, ESR, … Clinical NIHSS, … Comment … Too much info is better than too little

Example 1

Example 2

Same patient Death is an outcome, not an event

Example 3

Example 4

Example 5

Example 6

?

Example 7

Data from this SAE Data from another SAE (PE) on the same patient

1 or 2 SAEs?

SAE: Problems in trials Failure to report Too little diagnostic evidence submitted (or available) Chase other hospitals, fax available information Failure to report promptly If uncertain, ask Coordinating Centre

Summary: Explained AE/SAE processes If in doubt: ASK Check the protocol Check with the PI or other clinician Better data improves reporting process Reduced number of data queries Saves time for investigators and trial staff

Questions?